Cantor Fitzgerald Analysts Increase Earnings Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) – Analysts at Cantor Fitzgerald raised their FY2023 earnings estimates for Stoke Therapeutics in a research report issued on Tuesday, May 9th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($2.66) for the year, up from their previous estimate of ($2.69). Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.66) per share.

Several other equities research analysts have also recently issued reports on the stock. Wedbush cut their price objective on shares of Stoke Therapeutics from $33.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 7th. Bank of America upgraded Stoke Therapeutics from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $9.00 to $12.00 in a research report on Monday, May 1st. Credit Suisse Group lowered their price target on Stoke Therapeutics from $32.00 to $28.00 and set an “outperform” rating for the company in a report on Tuesday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of Stoke Therapeutics in a research report on Thursday, March 16th. Finally, Canaccord Genuity Group started coverage on shares of Stoke Therapeutics in a research report on Wednesday, April 26th. They set a “buy” rating and a $24.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $24.88.

Stoke Therapeutics Stock Down 0.5 %

Shares of NASDAQ:STOK opened at $11.44 on Friday. Stoke Therapeutics has a 52-week low of $6.88 and a 52-week high of $22.87. The business has a fifty day moving average of $9.02 and a two-hundred day moving average of $9.25. The stock has a market cap of $505.52 million, a P/E ratio of -4.63 and a beta of 0.41.

Stoke Therapeutics (NASDAQ:STOK – Get Rating) last issued its earnings results on Monday, March 6th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.06. Stoke Therapeutics had a negative return on equity of 47.86% and a negative net margin of 679.83%. The business had revenue of $3.27 million for the quarter, compared to analysts’ expectations of $2.93 million.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 24,967 shares of the business’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $10.00, for a total transaction of $249,670.00. Following the completion of the transaction, the insider now directly owns 86,758 shares of the company’s stock, valued at approximately $867,580. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in STOK. Great West Life Assurance Co. Can raised its holdings in shares of Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after purchasing an additional 1,078 shares in the last quarter. BlackRock Inc. lifted its holdings in Stoke Therapeutics by 0.8% during the 1st quarter. BlackRock Inc. now owns 1,845,495 shares of the company’s stock worth $15,373,000 after buying an additional 14,848 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Stoke Therapeutics by 0.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 293,632 shares of the company’s stock worth $2,446,000 after acquiring an additional 1,625 shares in the last quarter. Simplify Asset Management Inc. purchased a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $1,023,000. Finally, Cowen AND Company LLC increased its holdings in shares of Stoke Therapeutics by 338.3% in the 1st quarter. Cowen AND Company LLC now owns 3,279,142 shares of the company’s stock valued at $27,315,000 after acquiring an additional 2,531,065 shares during the last quarter.

Stoke Therapeutics Company Profile

(Get Rating)

Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.